Filing Flows › CG Oncology (CGON) › Q4 2025
CG Oncology (CGON) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 27, 2026
CG Oncology (CGON) reported revenue of $2.3M for the fourth quarter 2025 (Q4 2025), +409% from a year earlier and +39% from the quarter before.
CG Oncology, Q4 2025: revenue $2.3M (+409% year over year), net loss $41.3M, operating cash flow −$36.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.3M | +39% | +409% |
| Operating profit | −$48.7M | — | — |
| Net earnings | −$41.3M | — | — |
| Operating cash flow | −$36.2M | — | — |
What changed
Revenue was $2.3M in Q4 2025, up 409% year over year and up 39% from the previous quarter. Commercial and Development Revenue was the largest line at 74% of revenue.
Operating costs exceeded revenue by $48.7M, an operating margin of -2097.3%. Total costs grew 33% against revenue growth of 409%. The fastest-growing cost line was General & admin (+54%). The quarter ended with a net loss of $41.3M, narrower than the previous quarter's $43.8M loss.
Operating cash flow was −$36.2M. Non-cash charges added back $849K of depreciation and amortization and $7.2M of share-based compensation. Working capital and other items used $2.9M. Capital expenditures of $7K exceeded it, leaving free cash flow of −$36.2M.
Questions
What was CG Oncology's revenue in the fourth quarter 2025?
CG Oncology (CGON) reported revenue of $2.3M for the fourth quarter 2025 (Q4 2025), +409% from a year earlier and +39% from the quarter before.
Source: CG Oncology 10-K on SEC EDGAR.